Cat. No.: HY-N0247

Saikosaponin B1

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Saikosaponin B1 is a bioactive constituent of Radix Bupleuri. Saikosaponin B1 is an agonist of the 5-HT_2C receptor with an EC₅₀ of 147.41 μM. Saikosaponin B1 inhibits the Hedgehog (Hh) signaling pathway by targeting the transmembrane protein SMO. Sailosaponin B1 can reduce liver fibrosis. Saikosaponin B1 has anti-cancer activities thus can be studies in research for cancers such as Medulloblastoma (MB).

For research use only. We do not sell to patients.

Purity: 99.42%
CAS No.: 58558-08-0
Formula: C₄₂H₆₈O₁₃
Molecular Weight:780.98

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Saikosaponin B1 Chemical Structure

CAS No.: 58558-08-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

5-HT_2C Receptor

All STAT Isoforms :

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>50 μM Compound: 19	Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
Bcap37	IC₅₀	>50 μM Compound: 19	Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
Hep 3B2	IC₅₀	>50 μM Compound: 19	Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
HepG2	IC₅₀	>50 μM Compound: 19	Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
MCF7	IC₅₀	>50 μM Compound: 19	Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]

In Vitro

Saikosaponin B1 (10 nM-10 μM, 36 h) reduces the level of glioma-associated oncogene homolog (GLI)-luciferase activity in transfected Shh Light II cells with an IC₅₀ of 241.8 nM^[1].
Saikosaponin B1 (5 μM, 6-24 h) does not target GLI transcription factor and it downstream molecules, as Saikisaponin B1 shows no inhibition activity against PGE2 (HY-P3502B)-induced TCF/LEF and GLI activity in transfected LS174T cells, or TNF-α-induced NF-κB in HEK293T cell^[1].
Saikosaponin B1 (3 μM, 36 h) fails to inhibit GLI-luciferase activity increased by limiting negative regulation from SUFU in SUFU-knockout Shh Light II cells, indicating Saikosaponin B1 targets Hh pathway via upstream components of SUFU^[1].
Saikosaponin B1 (3 μM, 36 h) significantly prevents the increased of Gli1 mRNA expression induced by SAG (HY-12848) (a synthetic Hh pathway agonist binds to SMO) in Shh Light II cells with an IC₅₀ of 3.64 μM^[1].
Saikosaponin B1 (10 nM-10 μM, 72 h) significantly inhibits the proliferation of DAOY cell line (derived from nodular MB with GLI transcriptional activity)^[1].
Saikisaponin B1 (1-10 μM, 0-24 h) decreases expression of TGF-β1-induced HSC activation biomarkers^[2].
Saikisaponin B1 (0-10 μM) with biotin-label retains the inhibition activity of fibrotic protein expression in the activated HSC-T6 cells and shows the most remarkable binding to STAT3^[2].
Saikisaponin B1 (50 μM) with biotin-label pulls down the STAT3 protein but no obvious interactions with JAK2 or IL-6 in HSC-T6 cells, LX-2 cells, and mouse liver tissues^[2].
Saikisaponin B1 (1-10 μM) inhibits STAT3 phosphorylation in Tyr 705 but does not influence Ser 727 phosphorylation in HSC-t6 and LX-2 cells^[2].
Saikisaponin B1 (5-10 μM, 24 h) disrupts STAT3 dimerization even in the presence of IL-6 (20 ng/mL) at 10 μM in HSC-T6 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR ^[1]

Cell Line:

Shh Light II cells transfected with luciferase reporter plasmids and Renilla-TK construct
Concentration:

10 nM-10 μM
Incubation Time:

36 h
Result:

Significantly reduced the level of Gli1 and Ptch 1 mRNA (two transcriptional targets of GLI), which further confirmed the inhibition of Hh signaling.
Showed little cytotoxicity in response to effective concentrations in Shh Light II cells.

Western Blot Analysis ^[2]

Cell Line:

Rat HSC-T6 cells; human LX-2 cells
Concentration:

10 nM-10 μM
Incubation Time:

0-24 h
Result:

Inhibited the mRNA levels of the HSC activation biomarkers (α-SMA, collagen I, and vimentin) in TGF-β1-stimulated rat HSC-T6 cells.
Decreased expression of TGF-β1-induced α-SMA and Collagen I in human LX-2 cells and suggests that Saikisaponin B1 can reduce TGF-β1-induced HSC activation and matrix protein expression.

In Vivo

Saikosaponin B1 (30 mg/kg, i.p., daily for 18 d) significantly inhibits tumor growth and reduces Gli1 mRNA in tumor tissues in MB mice subcutaneously allografted with primary MB tumor tissues^[1].
Saikosaponin B1 (200 mg/kg, i.p., three times a week from week 4 to week 7) ameliorates the Thioacetamide (TAA) (HY-Y0698)-induced morphological changes and liver damage with decreased collagen deposition in TAA-induced liver fibrosis model^[2].
Saikosaponin B1 (10 mg/kg, s.c., twice a week for 4 weeks) attenuates the fibrosis histopathological characteristics of the liver tissues in CCl₄-induced liver fibrotic mice^[2].
Saikosaponin B1 (20 mg/kg, i.p., for 4 weeks) fails to further reduce liver fibrosis in response to CCl₄ in CCl₄mediated liver fibrosis STAT3 knockout mice model, suggesting STAT3 knockdown abrogated the antifibrosis effect of Saikosaponin B1^[2].
Saikosaponin B1 (2.5-10 mg/kg, i.p., once per day for 7 consecutive days) inhibits pulmonary edema in LPS (HY-D1056)-induced ALI mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

TAA (100 mg/kg, i.p., three times a week)-induced liver fibrosis male Balb/c mice model^[2]
Dosage:

5-20 μM, three times a week from week 4 to week 7
Administration:

Intraperitoneal injection (i.p.)
Result:

Decreased the liver/body weight ratio and the serum levels of ALT, AST, and TBIL compared to untreated model group.
Exerted a considerable effect on fibrosis alleviation with 10 mg/kg.

Animal Model:

CCl_4- (5 mg/kg of 40% CCl_{4_{in the first week, 3 mg/kg of 40% CCl_{4_{twice a week for another 6 weeks, s.c. )-induced liver fibrotic mice^[2]}}}}
Dosage:

10 mg/kg, twice a week for 4 weeks
Administration:

Subcutaneous injection (s.c.)
Result:

Exerted protective effect on liver function using the serum levels of ALT, AST, and TBIL.
Downregulated various proinflammatory cytokines (IL-6 and IL-1β) and fibrotic proteins (FN, collagen I , α-SMA and vimentin) in liver tissues.
Resulted in an obvious decrease in p-STAT3 and Gli1 expression levels.
Decreased STAT3 phosphorylation and Gli1 expression in the aHSCs and blocked interaction between STAT3 and Gli1.

Animal Model:

CCl_4- (5 mg/kg of 40% CCl_{4_{in the first week, 3 mg/kg of 40% LPS (5 mg/kg, i.p.)-induced ALI mic}}
Dosage:

2.5-10 mg/kg, once per day for 7 consecutive days
Administration:

Intraperitoneal injection (i.p.)
Result:

Significantly decreased the lung W/D ratios.
Significantly relieved the histological damage induced by LPS in mouse lungs.
Inhibited the expression of the inflammatory factors IL-6, IL-1β, and TNF-α in a dose-dependent manner.
Lowered TLR4 proteins and NF-κB proteins.

Chemical Information

CAS No. 58558-08-0
Appearance Solid
Molecular Weight 780.98
Formula C₄₂H₆₈O₁₃
Color White to off-white
SMILES

OC[C@@]1(C)[C@]2([H])CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(CO)CCC(C)(C)CC5=C4C=C[C@]3([H])[C@@]2(C)CC[C@@H]1O[C@]6([H])O[C@H](C)[C@H](O)[C@H](O[C@]7([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O
Structure Classification
- Saccharides
- Monosaccharides
Initial Source
- Plants
- Umbelliferae
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Biomater Res

Tryptamine-Functionalized Lipid Nanocarriers Co-delivering SMO/BRD4 Inhibitors for Synergistic Medulloblastoma Therapy. [Abstract]

2025 Aug 8:29:0237. PMID: 40785845
Phytomedicine

CBX5 loss drives Pl3Kδ inhibitor resistance in mantle cell lymphoma and propolis restores sensitivity by inducing CBX5-mediated ferroptosis. [Abstract]

2025 May 27:143:156911. PMID: 40466505

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (128.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2804 mL

6.4022 mL

12.8044 mL

5 mM

0.2561 mL

1.2804 mL

2.5609 mL

10 mM

0.1280 mL

0.6402 mL

1.2804 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 100 mg/mL (128.04 mM); Clear solution

This protocol yields a clear solution of ≥ 100 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1000.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 10 mg/mL (12.80 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 10 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 10 mg/mL (12.80 mM); Clear solution

This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Luo J, et al., Saikosaponin B1 and Saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathway. J Nat Med. 2022 Jun;76(3):584-593. [Content Brief]

[2]. Shao, M., et al., (2025), Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation. Exploration 270000.

[3]. Peng D, et L., Saikosaponin A and Its Epimers Alleviate LPS-Induced Acute Lung Injury in Mice. Molecules. 2023 Jan 18;28(3):967. [Content Brief]

[4]. Sun, C. L., et al., (2017). Bioassay-guided isolation of saikosaponins with agonistic activity on 5-hydroxytryptamine 2C receptor from Bupleurum chinense and their potential use for the treatment of obesity. Chinese journal of natural medicines, 15(6), 467–473. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2804 mL	6.4022 mL	12.8044 mL	32.0111 mL
	5 mM	0.2561 mL	1.2804 mL	2.5609 mL	6.4022 mL
	10 mM	0.1280 mL	0.6402 mL	1.2804 mL	3.2011 mL
	15 mM	0.0854 mL	0.4268 mL	0.8536 mL	2.1341 mL
	20 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6006 mL
	25 mM	0.0512 mL	0.2561 mL	0.5122 mL	1.2804 mL
	30 mM	0.0427 mL	0.2134 mL	0.4268 mL	1.0670 mL
	40 mM	0.0320 mL	0.1601 mL	0.3201 mL	0.8003 mL
	50 mM	0.0256 mL	0.1280 mL	0.2561 mL	0.6402 mL
	60 mM	0.0213 mL	0.1067 mL	0.2134 mL	0.5335 mL
	80 mM	0.0160 mL	0.0800 mL	0.1601 mL	0.4001 mL
	100 mM	0.0128 mL	0.0640 mL	0.1280 mL	0.3201 mL

Keywords

Saikosaponin B1

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Saikosaponin B1

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Saikosaponin B1

All STAT Isoforms

All Interleukin Related Isoforms

All TNF Receptor Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Saikosaponin B1 Related Classifications

Cat. No.: HY-N0247